B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
TRDA
Entrada TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The company did deliver favorable safety, no serious adverse events, normal kidney markers, and a statistically significant Time to Rise velocity signal in Cohort 1, while management argues the pediatric PK shortfall is now better understood and can be addressed with higher dosing in Cohort 2 [#8-K-2026-05-07]. If that explanation holds, the May 7 selloff may have overshot the remaining platform option value.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.6.
What can break
Cash runway extends only into Q3 2027, while Q1 2026 net loss was $39.7 million and collaboration revenue fell sharply year over year, so any meaningful delay or weak follow-up data could revive financing risk [#8-K-2026-05-07].
Momentum
17
Value
41
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $11.00 · Bear $4.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum17 · Δ7d -1.1
Value41 · Δ7d 0.0
Sentiment67 · Δ7d -1.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -1.6.
Contradictions & invalidation
- • Cash runway extends only into Q3 2027, while Q1 2026 net loss was $39.7 million and collaboration revenue fell sharply year over year, so any meaningful delay or weak follow-up data could revive financing risk [#8-K-2026-05-07].
- • Entrada said it will re-engage with the FDA before updating design and timing for ELEVATE-44-102, adding regulatory and execution uncertainty for the U.S. adult study [#8-K-2026-05-07].
- • The market reaction shows investors cared more about exposure and dystrophin magnitude than management’s functional read-through.
Catalyst clock
2026-05-31
Post-readout revision cycle may keep shares volatile after the May 7 reset
Lead driver: Sentiment · See AI snapshot
Momentum
17
9% active weight
Current posture
7d trendFlat
Δ7d
-1.1
Δ21d
-0.4
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
67
62% active weight
Current posture
7d trendSoftening
Δ7d
-1.6
Δ21d
-2.3
Why this grade
Composite grade C. Momentum 17.0 / Value 41.2 / Sentiment 67.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$285.02M
Beta
-0.12
Shares Out
38.94M
P/E (TTM) · Derived
-2.1
P/S (TTM)
6.52
P/FCF (TTM) · Derived
-2.28
Rev YoY
-53.9%
EPS YoY
-2.9%
Gross Margin
+21.2%
Op Margin
-3767.1%
Net Debt
-$245.42M
Current Ratio
10.89
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data